Home
Services
Financial Services
Banking
Investment Banking
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - December 2011

Investment Banking

Summary

Table of Contents

Data Series

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - December 2011

Publication date: December 2011

Keywords : venture capital, M&A deal, private equity, raise capital

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - December 2011 Summary GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - December 2011” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on...

Search ReportLinker

The Largest Collection of Market Research Reports

» 1.2 Million Industry Reports
» 450,000 Company Profiles

» 850,000 Market Briefings
» 40,000 Country Guides

From +200,000 authoritative sources

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - December 2011

Summary

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - December 2011” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Novemeber 2011. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the last six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Global Investment Banking Industry

1 Table of contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 6
2 Pharmaceuticals & Healthcare, Global, Deal Summary, 8
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, November 2011 8
2.2 Pharmaceuticals & Healthcare, Global, Top Deals, November 2011 10
2.2.1 Gilead Sciences To Acquire Pharmasset For $11 Billion 10
2.2.2 Amgen Completes Public Offering Of Senior Notes For $6 Billion 10
2.2.3 Teva Pharmaceutical Completes Public Offering Of Senior Notes For $5 Billion 10
2.2.4 Express Scripts Completes Private Placement Of Senior Notes For $4.1 Billion 11
2.2.5 Lundbeck Enters Into Co-Development Agreement With Otsuka Pharmaceutical 11
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals and Deal Values, November 2011 12
3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 13
3.1 Pharmaceuticals & Healthcare, Global, M&A, November 2011 13
3.1.1 Top M&A Deals in November 2011 14
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, June 2011-November 2011 15
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, November 2011 16
3.2.1 Top Equity Offering Deals in November 2011 17
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, June 2011 - November 2011 18
3.3 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, November 2011 19
3.3.1 Top Debt Offering Deals in November 2011 20
3.3.2 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, June 2011 - November 2011 21
3.4 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, November 2011 22
3.4.1 Top PE/VC Deals in November 2011 23
3.4.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, November 2011 24
3.4.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, November 2011 25
3.4.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, June 2011 - November 2011 26
3.4.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, June 2011 - November 2011 27
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, November 2011 28
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, November 2011 28
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, June 2011 - November 2011 29
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), November 2011 30
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, November 2011 31
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), June 2011 - November 2011 32
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals and Deal Values (US$ m), June 2011 - November 2011 33
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), June 2011 - November 2011 34
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, November 2011 35
5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, November 2011 35
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2011 36
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, November 2011 37
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, September 2011 37
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, September 2011 38
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), June 2011 - November 2011 39
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), June 2011 - November 2011 40
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), June 2011 - November 2011 41
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), June 2011 - November 2011 42
6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 43
6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, November 2011 43
6.1.1 Oncology - Deals of the Month 44
6.2 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, November 2011 46
6.2.1 Infectious Diseases - Deals of the Month 47
6.3 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, November 2011 48
6.3.1 Central Nervous System - Deals of the Month 49
6.4 Pharmaceuticals & Healthcare, Global, Metabolic Disorder Deals, November 2011 50
6.4.1 Metabolic Disorders - Deals of the Month 51
6.5 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, November 2011 52
6.5.1 Cardiovascular - Deals of the Month 53
6.6 Pharmaceuticals & Healthcare, Global, Immunology Deals, November 2011 54
6.6.1 Immunology - Deals of the Month 55
6.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals, November 2011 56
6.7.1 Gastrointestinal - Deals of the Month 57
7 Deal Summary by Geography 58
7.1 Pharmaceuticals & Healthcare, North America Deals, November 2011 58
7.1.1 North America - Deals of the Month 59
7.2 Pharmaceuticals & Healthcare, Europe, Deals, November 2011 60
7.2.1 Europe - Deals of the Month 61
7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, November 2011 62
7.3.1 Asia-Pacific - Deals of the Month 63
7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, November 2011 64
7.4.1 Rest of the World - Deals of the Month 65
8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 66
8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, June 2011 - November 2011 66
8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, June 2011 - November 2011 67
9 Further Information 68
9.1 Methodology 68
9.2 About GlobalData 68
9.3 Contact Us 69
9.4 Disclosure information 69
9.5 Disclaimer 69

List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 9
Table 2: Pharmaceuticals & Healthcare, Global, Top Deals, November 2011 10
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), November 2011 12
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 13
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, November 2011 14
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, June 2011 - November 2011 15
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 16
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, November 2011 17
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 18
Table 10: Pharmaceuticals & Healthcare, Global, Debt Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 19
Table 11: Pharmaceuticals & Healthcare, Global, Top Debt Offering Deals, November 2011 20
Table 12: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Summary, Number of Deals and Deal values (US$ m), June 2011 - November 2011 21
Table 13: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 22
Table 14: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, November 2011 23
Table 15: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, June 2011 - November 2011 24
Table 16: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), November 2011 25
Table 17: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 26
Table 18: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, June 2011 - November 2011 27
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 28
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 29
Table 21: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), June 2011 - November 2011 30
Table 22: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), November 2011 31
Table 23: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), June 2011 - November 2011 32
Table 24: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2011 - November 2011 33
Table 25: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), June 2011 - November 2011 34
Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 35
Table 27: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), June 2011 - November 2011 36
Table 28: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Deal Value, November 2011 37
Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, September 2011 37
Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, September 2011 38
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal values (US$ m), June 2011 - November 2011 39
Table 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), November 2011 40
Table 33: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, June 2011 - November 2011 41
Table 34: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), November 2011 42
Table 35: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 44
Table 36: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 46
Table 37: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 48
Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 51
Table 39: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 52
Table 40: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 54
Table 41: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 56
Table 42: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 59
Table 43: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 60
Table 44: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 62
Table 45: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 64
Table 46: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 66
Table 47: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 67

List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 8
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%) and Deal Values (%),November 2011 12
Figure 3: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 13
Figure 4: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, June 2011 - November 2011 15
Figure 5: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 16
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 18
Figure 7: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 19
Figure 8: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 21
Figure 9: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 22
Figure 10: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, June 2011 - November 2011 24
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%) and Deal Values (%), November 2011 25
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 26
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 28
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 29
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), June 2011 - November 2011 30
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), June 2011 - November 2011 32
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2011 - November 2011 33
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), June 2011 - November 2011 34
Figure 19: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 35
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), June 2011 - November 2011 36
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 39
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), June 2011 - November 2011 40
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals and Deal Values (US$ m), June 2011 - November 2011 41
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), November 2011 42
Figure 25: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 43
Figure 26: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 46
Figure 27: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 48
Figure 28: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 50
Figure 29: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 52
Figure 30: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 54
Figure 31: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 56
Figure 32: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 58
Figure 33: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 60
Figure 34: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 62
Figure 35: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 64
Figure 36: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 66
Figure 37: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 67

Companies mentioned

Talk to Robyn

00 1 718 213 49 04

Send Your Request

Follow

Add to circles Subscribe to our RSS feeds!

Global Investment Banking Industry : Latest Reports

Merger and Acquisition Trends in the Global Automotive OEM Industry

$ 6 000
Industry report
April 2013
by Frost & Sullivan

M&As Gain Importance as Financing Options in the Automotive OEM Industry This research service analyzes merger and acquisition trends in the global automotive industry with respect to year, deal volume, ...

Global Backend-as-a-service Market 2012-2016

$ 2 000
Industry report
February 2013
by Infiniti Research Limited

TechNavio's analysts forecast the Global Backend-as-a-Service (BaaS) market to grow at a CAGR of 100.9 percent over the period 2012-2016. One of the key factors contributing to this market growth is the ...

Power Quarterly Deals Analysis: M&A and Investment Trends - Q4 2012

$ 1 500
Industry report
January 2013
by Global Data

Power Quarterly Deals Analysis: M&A and Investment Trends - Q4 2012 Summary GlobalData's ?Power Quarterly Deals Analysis: M&A and Investment Trends - Q4 2012? report is an essential source of data and ...

Partnerships, Licensing, Investments And M ...

January 2013 $ 1 500

Power Quarterly Deals Analysis: M&a And In ...

April 2013 $ 1 500

Partnerships, Licensing, Investments And M ...

April 2013 $ 1 500

Corporate Financing Week - Yearly Subscrip ...

April 2013 $ 1 088

Global Macro Monitor - All Regions Edition ...

April 2013 $ 1 088

Global Macro Monitor - Asia Edition - Year ...

April 2013 $ 1 088

Partnerships, Licensing, Investments And M ...

February 2013 $ 1 000

More Reports:

Investment Banking in Australia (26)

Investment Banking in China (31)

Investment Banking in France (32)

Investment Banking in Germany (23)

Investment Banking in India (24)

Investment Banking in Italy (20)

Investment ... in the United Kingdom (23)

Investment ... in the United States (127)

Company Reports

Biogen Idec

Hsbc Equipment Finance Ltd.

Hutchison Telephone Company Ltd.

Solucient L.L.C.

Appcelerator Inc.

Global Investment Banking Industry : Latest Downloads

Bond Market Business Analysis

Industry report
April 2013
56 pages

... For bonds to the right at the same time that the supply curve for bonds shifts to the right because of the deficit. If nothing else changes, an increase in government borrowing shifts the bond supply curve ...

World Investment Banking Industry

Industry report
April 2013
15 pages

... Target equity returns: 5-20% debt: 3-6%; actual returns n/a vc/pe equity target returns 10-20%+; actual returns: -51% to 106% corporate investment (indirect) project investment (direct) investment fund ...

Debt Market Business Brief

Industry report
March 2013
8 pages

... That the local corporates turned to the foreign currency debt market rather than the loan market to obtain funding. This might be a sign that the debt market had gained ground against the loan market ...

More Reports:

Investment Banking in Australia (24)

Investment Banking in Canada (23)

Investment Banking in China (34)

Investment Banking in India (70)

Country Reports

World

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.